Abivax shares fell 30% in morning trading Tuesday after the firm reported late-stage trial data for its inflammatory bowel drug. The selloff follows a 16-fold rally in the stock last year and led losses on Europe's STOXX 600 benchmark index. Investors are weighing strong efficacy results against safety concerns involving three cancer cases reported during the maintenance study.

Strong Efficacy Meets Safety Headwinds